Table 3.
Predictive factors between treatment continuation and discontinuation groups.
| Characteristics | Continuation (n = 11) |
Discontinuation (n = 17) |
p Value |
|---|---|---|---|
| Age (years) | 71 (58, 87) | 76 (56, 89) | 0.085 † |
| Sex: Male/Female | 10/1 | 12/5 | 0.160 * |
| Etiology: HBV and HCV/non-viral | 5/6 | 8/9 | 0.479 * |
| ECOG PS: 0/≥1 | 11/0 | 14/3 | 0.171 * |
| Naïve/recurrence HCC | 3/8 | 10/7 | 0.106 * |
| Child–Pugh score: 5/≥6 | 9/2 | 5/12 | 0.009 * |
| mALBI grade: 1 and 2a/2b and 3 | 9/2 | 6/11 | 0.020 * |
| BCLC stage: A and B/C | 3/8 | 10/7 | 0.106 * |
| Portal vein invasion: Yes/No | 4/7 | 3/14 | 0.250 * |
| Metastasis other organs: Yes/No | 3/8 | 5/12 | 0.624 * |
| AFP (ng/mL) | 40 (0.7, 17,483) | 590 (1.4, 769,600) | 0.166 † |
| DCP (mAU/mL) | 419 (14, 28,256) | 651 (41, 136,617) | 0.076 † |
| NLR | 3.18 (1.63, 6.52) | 3.07 (1.19, 25.7) | 0.101 † |
Values are presented as median (minimum, maximum) or number. † p-value with continuous variables were obtained by Mann–Whitney U test. * p-value with categorical carriables were obtained by the Fisher’s exact test. HBV—hepatitis B virus; HCV—hepatitis C virus; non-viral, alcoholic, non-alcoholic steatohepatitis and autoimmune hepatitis; ECOG—Eastern Cooperative Oncology Group; PS—performance Status; HCC—hepatocellular carcinoma; mALBI—modified albumin-bilirubin; BCLC—Barcelona Clinic Liver Cancer; AFP—alpha-fetoprotein; DCP—des-gamma-carboxy prothrombin; NLR—neutrophil–to–lymphocyte ratio.